All News
Beyond immunosuppression, Dr. Carol Langford reviews non-med management of GPA upper airway disease. Things to consider for patients and will change the way I practice. @rheumnow #RNL2023 https://t.co/4SlYx1r5ZK
Dr. Rachel Tate uptoTate ( View Tweet)
Avacopan in GPA
- non-inferior to prednisone for induction remission
- received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids
- should be used in newly diagnosed active or relapsing disease
@rheumnow #RNL2023 https://t.co/0DL1WUP177
Robert B Chao, MD doctorRBC ( View Tweet)
Dr. Langford's take home for GPA. Remember to consider disease severity (will determine tx,) maintenance tx, and non-medical management including vaccination options for pts. #RNL2023 @RheumNow https://t.co/HWdv3Fv9zK
Dr. Rachel Tate uptoTate ( View Tweet)
Limitations of IL6 and some unanswered questions in GCA ? By Dr.Robert Spiera #RNL2023 @RheumNow https://t.co/3tJpRhmFAJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Sirilumab ( SAPHYR trial) in PMR, By Dr.Robert Spiera #RNL2023 @RheumNow
It also improved patient reported outcomes. Great news👌 https://t.co/NDxhIwvACq
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Preterm deliveries in PsA pregnancies were more pronounced with 1- first pregnancy.
2- Discontinuation of biologic prior to pregnancy.
By Dr.Chambers #RNL2023 @RheumNow https://t.co/CxZh0ak4l0
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Neonatal outcomes:
Small for gestational age more common with an Adjusted OR off 2.42 and statistically significant.
By Dr.Chambers #RNL2023 @RheumNow https://t.co/NFMAEROEEM
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Pregnancy and #PsA
Risk of preterm delivery if
➡️first pregnancy
➡️biologic stopped pre-pregnancy
Dr Chambers at #RNL2023 https://t.co/yImZRwMuI8
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Why JAKinibs in PsA ?! By Eric Ruderman #RNL2023 @RheumNow
Also inflammatory bowel disease and most recently Upadacitinib for crohns disease. https://t.co/loUgJNUsKT
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 @RheumNow
Good news, especially with Updacitinib recently and Crohn’s disease ( full package). https://t.co/nlBWJhzpLp
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
What influences global scores to patients is different from physicians by Laura Coates #RNL2023 @RheumNow https://t.co/bTKozGeON6
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Patients definition of remission in PsA, by Laura Coates #RNL2023 @RheumNow https://t.co/kphM14SH0E
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#RNL2023
AGATA trial showed benefit of Abatecept in GCA - 48 to 31% disease free survival
Robert Spiera
@RheumNow https://t.co/pPzbdTTvEi
Eric Dein ericdeinmd ( View Tweet)
#RNL2023
Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications"
No prospective studies, 2 large retrospective studies suggesting benefit
@RheumNow https://t.co/OedVG03yN3
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 Resources for pregnancy and lactation for patients on various #medications and #chronic #diseases. Have a look. Pregnant 🫃 #baby and #breast #feeding. https://t.co/A8zmBUAylG
Janet Pope Janetbirdope ( View Tweet)
Is there role for MTX in GCA
Favorable results in a meta-analysis with NNT 11 to prevent 1 cranial relapse
BUT: limitations of meta-analysis, short follow-up, dose response not evaluated
Robert Spiera at #RNL2023 @RheumNow https://t.co/sHx2ceVmAi
Eric Dein ericdeinmd ( View Tweet)
DMARDs/TNF for PMR:
MTX- initial benefit, but no 5 year steroid sparing effect
Infliximab - no benefit
Lef - some benefit in case series
Robert Spiera #RNL2023 @RheumNow https://t.co/cmwGEWHQEO
Eric Dein ericdeinmd ( View Tweet)
IL-6 for PMR
SPARE and SEMAPORE (Toci), SAPHYR (Sari)
2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off
Robert Spiera @RheumNow #RNL2023 https://t.co/quOWjJjgB3
Eric Dein ericdeinmd ( View Tweet)
Dr. Robert Spiera on Recent IL-6i in PMR treatment:
SPARE and SEMAPHORE study - Tocilizumab
SAPHYR - Sarilumab (now FDA approved for PMR tx)
@RheumNow #RNL2023 https://t.co/gofe54wSjo
Robert B Chao, MD doctorRBC ( View Tweet)
SAPHYR, presented at #ACR22, unpublished
Robert Spiera at #RNL2023
Phase 3 study for refractory PMR
Sustained remission of disease, less steroids usage, steroid toxicity, and improved PROs
@RheumNow https://t.co/k3w2TQ3yEB
Eric Dein ericdeinmd ( View Tweet)